IN B00007
Alternative Names: IN-B00007; IN-B020Latest Information Update: 05 Apr 2024
At a glance
- Originator CJ Cheiljedang Corp.
- Developer HK inno.N
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Cancer
Most Recent Events
- 29 Mar 2024 IN B00007 is available for licensing as of 29 Mar 2024. https://www.inno-n.com/eng/esg/csr/co_prosperity/esg_support
- 31 Jul 2023 Early research in Cancer in South Korea (unspecified route) prior to July 2023 (HK inno.N pipeline, March 2024)
- 18 Jun 2020 CJ HealthCare is now called HK inno.N